Page 121 - Haematologica June

CD
EF
Figure 2. Indicators for predicting prognosis in terms of overall survival in adult-onset chronic active Epstein-Barr virus (EBV) infection patients. Although infected- cell type (A) and histological classification (B) were not prognostic factors for overall survival (P=0.587 and P=0.822, respectively), thrombocytopenia (B), platelet count < 100×109/L), EBNA antibody titer ≥ 40 (C), the presence of hemophagocytosis syndrome (HPS) (D) at the initial diagnosis were poor prognostic indicators for overall survival (P=0.0087, P=0.0236, and P=0.0149, respectively). With regards to treatment, allogeneic HSCT improved survival (F) (P=0.0289). CAEBV: chronic active EBV infection; EBNA: Epstein–Barr virus nuclear antigen 1; EBV: Epstein-Barr virus; HPS: hemophagocytic syndrome; HSCT: hematopoietic stem cell transplan- tation.
Adult patients with chronic active EBV-like features
Clinicopathological analysis of patients diagnosed at over 50 years of age with chronic active Epstein-Barr virus infection
The clinical characteristics of CAEBV patients diag- nosed at over 50 years of age are presented in Table 2. Eight out of 9 cases (88.9%) showed EBV monocolonality by Southern blot analysis. However, in our study, there
was no difference in clinical features between all CAEBV cases and those aged over 50 years. Furthermore, as shown in Online Supplementary Figure S4, we performed a prognostic analysis based on the log-rank test by compar- ing CAEBV in patients aged 50 years or older and those under 50 years. However, there was no difference in over- all survival between these two groups (P=0.922).
AB
haematologica | 2018; 103(6)
1023